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Lung cancer represents a major worldwide health concern; although advances in patient
management have improved outcomes for some patients, overall 5-year survival rates
are only around 15%. In vitro studies and mouse models are commonly used to study
lung cancer and their use has increased the molecular understanding of the disease.
Unfortunately, mouse models are poor predictors of clinical outcome and seldom mimic
advanced stages of the human disease. Animal models that more accurately reflect
human disease are required for progress to be made in improving treatment outcomes
and prognosis. Similarities in pulmonary anatomy and physiology potentially make
sheep better models for studying human lung function and disease. Ovine pulmonary
adenocarcinoma (OPA) is a naturally occurring lung cancer that is caused by the
jaagsiekte sheep retrovirus. The disease is endemic in many countries throughout the
world and has several features in common with human lung adenocarcinomas, including
histological classification and activation of common cellular signaling pathways. Here we
discuss the in vivo and in vitro OPA models that are currently available and describe the
advantages of using pre-clinical naturally occurring OPA cases as a translational animal
model for human lung adenocarcinoma. The challenges and options for obtaining these
OPA cases for research purposes, along with their use in developing novel techniques for
the evaluation of chemotherapeutic agents or for monitoring the tumor microenvironment
in response to treatment, are also discussed.
Keywords: human lung cancer, jaagsiekte sheep retrovirus, ovine pulmonary adenocarcinoma, sheep lung cancer
models, comparative oncology
HUMAN LUNG CANCER
Lung cancer is the most commonly diagnosed cancer in the world, with ∼1.8 million new
cases and 1.6 million cancer-related deaths recorded each year (1). Lung cancer treatment can
be challenging as most patients are diagnosed when the disease is at an advanced stage. Poor
response rates to radio-and chemotherapy have meant that overall 5-year survival rates are only
15%. The disease is highly heterogenous and is divided into several subtypes; their classification
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is under periodic review and in 2011 a multidisciplinary
classification system was proposed by the European Respiratory
Society and International Association for the Study of Lung
Cancer (2). Their classification was based on factors such
as disease biology, pathogenesis, and histopathology, which
rendered terms such as bronchioloalveolar carcinoma (BAC) and
it’s mucinous and non-mucinous forms redundant.
Lung cancer is broadly classified into small-cell lung cancer,
originating from bronchial neuroendocrine cells, and non-small
cell lung cancer (NSCLC), originating from lung epithelial
cells. NSCLC accounts for ∼80% of cases and is subdivided
into adenocarcinomas, large-cell carcinomas, squamous cell
carcinomas, mixed, and undifferentiated tumors (3).
Adenocarcinomas are the most common form of lung
cancer, accounting for 40% of cases. Hyperplasia of lung
epithelial cells is thought to be the earliest cellular change
that occurs in adenocarcinoma tumourigenesis. Termed
“atypical adenomatous hyperplasia,” these pre-malignant lesions
can accumulate cellular genetic abnormalities causing the
cells to become pleomorphic, demonstrating a non-invasive,
lepidic growth pattern along alveolar walls (4). Although
these growths are known as adenocarcinoma-in-situ, complete
surgical resection of lesions <30mm in diameter results in
almost 100% of cases gaining 5-year disease-free survival.
However, if untreated, these lesions develop into invasive
adenocarcinomas. Minimally invasive adenocarcinomas are
lesions <30mm in diameter with an invasive component
<5mm; surgical resection of these lesions is still likely to
give an excellent prognosis. The cellular growth pattern
(lepidic, acinar, papillary, or solid) is used to classify invasive
adenocarcinomas >30mm in diameter; these invasive forms
are the most common clinical and pathological presentation
of the disease. Lepidic-predominant adenocarcinoma describes
invasive adenocarcinomas that have a predominant lepidic
pattern with an invasive component >5mm (previously termed
non-mucinous BAC). In addition, a mucinous form of lepidic
adenocarcinoma may also be encountered (previously termed
mucinous BAC); this non-invasive, minimally-invasive or
invasive disease is often bilateral and multifocal with extensive
mucous production. Patients suffering from this subtype present
with a cough and extensive mucous production that can lead to
death from respiratory failure without any evidence of invasive
disease (2).
MOUSE MODELS OF HUMAN
LUNG CANCER
Numerous animal models (primates, dogs, hamsters, mice)
have been described for lung cancer research (5, 6). Mice
have traditionally been considered the preferred model due
to cost-effectiveness and ease of genetic manipulation (7).
Many mouse models are now available, including inbred
strains exhibiting high rates of spontaneous lung tumors (8–10)
(useful for chemoprevention studies), chemical (11)/carcinogen
(5)/environmental-induced lung cancer models (12) (allowing
the study of tumor initiation and progression) and orthotopic
xenograft models (13–16) (facilitating the analysis of both
primary and metastatic tumors). Hundreds of transgenic mouse
strains which incorporate the genetic mutations that occur
in human lung cancer can now be produced. These mice
will produce tumors with greater similarity to human disease
and allow the genes that drive lung cancer development
and progression to be identified (17). These genetic changes
include tumor suppressor gene inactivation (p53, retinoblastoma,
and p16), oncogene activation (K-ras), altered growth factor
expression (18), loss of heterozygosity, and amplification of
specific chromosomal regions (17, 19). The use of bioluminescent
or fluorescent reporters in mice is also possible (20, 21).
These models allow lineage tracing to be performed and can
lead to the identification of individual oncogenes involved in
tumourigenesis and can enable the determination of the tumor
cell type origin (22).
Despite these advantages, murine models do not accurately
represent the advanced stages of lung cancer and are poor
predictors of clinical outcome. Each model also has its own
specific disadvantages, such as a lack of metastasis in genetic and
chemically induced models and the inability to examine immune
response in tumor development/progression in xenograft models
that require the use of immunodeficient mice (7). The perceived
advantages of having multiple models can also be seen as a
limitation, as no one single model can be used to examine all
stages of the disease.
COMPARATIVE HUMAN AND SHEEP
PULMONARY ANATOMY
AND PHYSIOLOGY
Similarities between human and sheep pulmonary anatomy
and physiology has led to sheep being identified as an
excellent model for investigating human lung function and
disease. Human lung anatomy consists of the left lung
divided into superior and inferior lobes and the right into
superior, middle and inferior lobes. Sheep anatomy is similar
with the left lung divided into cranial and caudal lobes
and the right into cranial, middle, caudal, and accessory
lobes. In sheep each lobe is separated by tissue septa, which
limits lobular connectivity (23) (Figure 1). Although in sheep
the right cranial lobe bronchus arises directly from the
trachea before the tracheal bifurcation (24), with respiratory
bronchioles that are poorly developed (23) the remaining
tracheobronchial tree is similar in both species, showing an
irregular dichotomous branching pattern. The distribution of
differentiated respiratory epithelial cells (25), mast cells (26),
and airway smooth muscle (27) is also comparable between
the species. Although human lungs have fewer intravascular
macrophages compared with the large number seen in sheep
lungs (28), increased numbers can occur after an endotoxic
insult. Lung development is also similar between the species;
lamb lungs show significant similarities to human infant
lungs, including prenatal alveologenesis, airway branching
patterns, bronchiolar club cell number, type II alveolar epithelial
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FIGURE 1 | Ovine and human comparative gross anatomy. (A) Ovine lower respiratory tract. (B) Human lower respiratory tract.
(pneumocytes) development, and the presence of airway
submucosal glands (29).
Similarities in lung size allow sheep models to be used
in ways not available in mouse models; techniques including
drug administration, advanced imaging (30), ultrasound (31),
endoscopy, and surgical procedures can be used in sheep as
they would in humans (32). With the correct animal handling
facilities, where appropriate, procedures can be performed in
conscious or minimally sedated animals, rather than using
general anesthesia. Repeated blood sampling and tissue collection
is easier in sheep and their longevity allows chronic conditions
to be modeled, while also enabling the evaluation of long-term
treatments. These factorsmake sheep excellentmodels for human
respiratory conditions (24) such as asthma (33), cystic fibrosis,
chronic obstructive respiratory disease (34), respiratory syncytial
virus infection (35), and now cancer (36).
OVINE PULMONARY ADENOCARCINOMA
Ovine pulmonary adenocarcinoma (OPA) is a neoplastic lung
disease caused by the jaagsiekte sheep retrovirus (JSRV) (37–40).
This betaretrovirus is the only known virus capable of inducing
the formation of naturally occurring lung adenocarcinomas.
Since the disease was first described in South Africa in the
nineteenth century (41), JSRV infection has been identified
in numerous sheep breeds and small ruminants throughout
the world, the virus however has never been shown able to
infect humans (42, 43). Although natural JSRV infection can
occur in goats this rarely results in tumor formation and
experimental infection of goat kids induces tumors with a
different macroscopic and histological appearance to those seen
in lambs (44). OPA is endemic in the UK and represents a
major economic and animal welfare concern (39, 45). Within-
flock disease incidence levels can be as high as 30%, although
levels of 2–5% are more common (46). Mortality rates of 50%
can be seen following initial disease identification within a flock
(47); however, as the disease becomes endemic rates reduce
to 1–5% (41, 48). Disease transmission occurs predominantly
through the aerosol route (41, 47, 49), meaning close contact
with infected sheep is a significant risk factor. The virus has
been detected in the milk and colostrum of infected ewes,
which poses a potential source of infection for new born
lambs (50).
JSRV BIOLOGY
JSRV particles contain two copies of single-stranded positive
sense RNA. It’s genome of ∼7,460 nucleotides contains four
genes encoding viral proteins (39). These four genes are: gag
(encoding the matrix, capsid, and nucleocapsid proteins); pro
(encoding aspartic protease); pol (encoding reverse transcriptase
and integrase enzymes); and env (encoding surface and
transmembrane envelope glycoproteins) (51, 52). An additional
open reading frame, known as orfX, which overlaps with the pol
gene, has also been identified; however, it is not required for in
vitro cellular transformation (53) or in vivo oncogenesis (54–
56). Interestingly, JSRV-induced neoplastic transformation is
mediated by the viral Env glycoprotein, although themechanisms
underlying this process are not completely understood. The
transforming activity of Env was first shown in vitro using rodent
fibroblasts (53, 57), with subsequent in vivo experiments showing
that the administration of viral vectors expressing Env to the
lungs of mice (56) and sheep (55) results in adenocarcinoma
formation. Env localization at the plasma membrane may enable
it to interact with other molecules such as protein kinases
(58), leading to the activation of downstream pathways that
promote cellular proliferation and survival. The Ras-MEK-
ERK (59, 60) and PI3K-AKT-mTOR (59, 61, 62) pathways
are commonly activated in OPA tumors; others may include
EGFR, RON-HYAL2 and heat shock proteins (63). Following
pathway activation, it is likely that further mutations are required
for tumors to develop, such as telomerase activation (62),
the activation of other cellular oncogenes or the inactivation
of tumor-suppressor genes. For a detailed description of
JSRV structure and replication cycle see the recent review by
Youssef et al. (36).
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ENDOGENOUS RETROVIRUS AND
IMMUNE RESPONSES
Endogenous retroviruses are viruses that have become integrated
into host germ-line DNA and are passed through the generations.
The sheep genome contains numerous endogenous JSRV
(enJSRV) related proviruses with over 90% sequence similarity to
exogenous JSRV (exJSRV) (64, 65). These enJSRV proviruses are
not oncogenic (they lack the oncogenic Env c-terminal domain
present in exJSRV) (37, 51, 66, 67), but are transcriptionally
active, with studies showing viral RNA and protein expression
in the female reproductive tract and in fetal tissues (67, 68).
The expression of these viral proteins may help protect the host
from exJSRV infection, either by receptor competition or through
the prevention of exJSRV viral particle transport and cellular
exit (68, 69).
JSRV infection lacks a specific cellular or humoral immune
response to viral proteins. Although neutralizing antibodies
specific for JSRV have been found in a minority of infected
animals (44, 70), the lack of a consistent adaptive response
is likely due to sheep being immunologically tolerant of JSRV
antigens as a result of the expression of enJSRV proteins in
the fetal thymus during T lymphocyte development. Tumor
cells also downregulate the expression of class I antigens of the
major histocompatibility complex, preventing their recognition
by CD8+ T lymphocytes. The influx of alveolar macrophages
following JSRV infection, which produce large amounts of
interferon gamma, also fails to activate T cells or produce a
JSRV-specific immune response. Overproduction of surfactant
proteins in OPA is also proposed to contribute to the absence of
an effective immune response (71).
OPA HISTOLOGY AND COMPARISON
WITH HUMAN LUNG ADENOCARCINOMAS
OPA tumors are composed of non-encapsulated neoplastic foci
originating from JSRV infected and transformed bronchiolar and
alveolar secretory epithelial cells (72, 73). Type II pneumocytes
are the predominant cell type, with smaller numbers of
bronchiolar club cells and undifferentiated cells present (74).
Type II pneumocytes function to synthesize, store, and secrete
alveolar surfactant, whereas bronchiolar club cells produce
protein components that line the extracellular surface of
bronchioles. Tumor cells are typically cuboidal or columnar,
with or without cytoplasmic vacuolation while also exhibiting
a low mitotic rate. However, other tumor areas may show
higher degrees of malignancy with high mitotic rates and areas
of necrosis (74, 75). Fibrovascular connective tissue surrounds
tumor cells and acts as a scaffold for the influx of inflammatory
cells. Large numbers of macrophages are typically identified (71);
however, neutrophil number can vary depending on the presence
of a bacterial co-infection (Figure 2). Tumor cell proliferation
initially occurs along alveolar septa (lepidic growth), before
extending into bronchioles through the formation of acinar or
papillary proliferations. Infected cells release JSRV virions which
spread within the lung forming new foci of infection, resulting
in a highly oligoclonal tumor (76). Neighboring tumor foci
eventually expand and coalesce to form a single large tumor.
Intrathoracic and extrathoracic metastasis is possible and has
been identified in∼10% of cases (77–80).
Although early reports detailing OPA described the disease as
having similarity to human BAC, under the current human lung
classification system early OPA lesions would fit a description
of a minimally invasive adenocarcinoma or lepidic-predominant
adenocarcinoma; whereas typical advanced lesions would more
closely resemble adenocarcinoma with a papillary or acinar-
predominant growth pattern. Importantly, OPA has the greatest
similarity to the rare multifocal, non-invasive presentation of
human lung adenocarcinoma (such as the mucinous forms), and
is less similar to the more common aggressive, metastatic forms
of the disease (36).
EXPERIMENTAL SYSTEMS FOR
STUDYING OPA
An in vivo sheep model was the first reproducible experimental
system developed to study OPA. Initial studies showed that the
injection of OPA tumor homogenates or JSRV purified from lung
fluid, into the trachea of healthy sheep, led to the appearance of
lung tumors (81, 82). It was later shown that using neonatal lambs
improved the rate of infection and decreased the time for tumors
to develop (73, 83). Further refinement of the model has been
achieved through cloning and sequencing of the JSRV genome
(51, 84) and the generation of an oncogenic and infectious
molecular clone, which has enabled virus production using in
vitro transfection of cell lines (85, 86). A JSRV replication-
defective virus (JS-RD) that expresses only the Env glycoprotein
has also been used in the in vivo lamb model system (55). As this
vector is replication defective, it can infect and transform target
cells but cannot replicate further. As these transformed cells
proliferate, they form well-isolated uniform neoplastic foci, each
being a separate transformed focus. Therefore, tumors induced
by JS-RD have a reduced degree of polyclonality compared to
naturally occurring OPA and human adenocarcinomas. This
reduced heterogeneity might add value to the experimental OPA
model, as the effects of targeting specific pathways would be
easier to identify.
The in vivo lamb model also has the potential for studying
pathogenic mechanisms in early stage disease. This is important
as human clinical tissue from early cases is generally unavailable.
However, while the lamb model is useful for studying OPA from
initial infection up to the formation of small tumors, for welfare
reasons it is not appropriate to let the disease reach an advanced
clinical stage. As such, naturally occurring cases are more suitable
for studying more advanced disease stages.
Mouse OPA models are alternative in vivo systems that do
not necessitate the use of large animal facilities. Using both
immunodeficient mice (56) and immunocompetent mice models
(87) studies have shown that the intranasal administration of
adeno-associated virus vectors encoding JSRV Env leads to the
formation of lung adenocarcinomas that are comparable to those
found in sheep and humans.
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FIGURE 2 | Histological appearance of OPA tumors. (a–c) OPA haematoxylin and eosin stained sections. (a) Columnar tumor cells can be seen lining the alveolar
septa (black arrows), forming acinar, or papillary proliferations. Two groups of neutrophils are present between the tumor cells (red arrows). (b) Alveolar macrophages
can be seen at the top right-hand side of the image and are characterized by large amounts of foamy cytoplasm. (c) Accumulation of mononuclear immune cells,
mostly lymphocytes, and plasma cells, can be observed at the top left-hand side of the image. (d) Masson’s trichrome stained section. Collagen is stained blue and
can be identified surrounding the tumor cells (yellow arrow heads), acting as a scaffold for the influx of inflammatory cells.
The lack of a cell line that can support JSRV replication
in vitro has limited the amount of in vitro research that has
been performed on OPA (88). Some studies have therefore
focused on the use of primary OPA tumor cells (62, 89, 90);
however, extended in vitro culture of these cells typically leads
to a cessation in virus production (89, 90). These alterations in
JSRV expression can be either delayed or reversed when cells are
cultured in a 3D environment (89, 91), indicating that 3D culture
models may more accurately recreate the oncogenic events that
occur in OPA. Lung tissue explants are another in vitro model
that has been developed. These precision-cut lung slices are tissue
discs 300µm thick and 8mm in diameter cut using an automated
microtome (59, 92), and are thought of as a transitional model
between the other in vitro and in vivo available systems.
OPA AS A MODEL FOR STUDYING
PULMONARY ADENOCARCINOMA
TUMOURIGENESIS
It is not clear whether human pulmonary adenocarcinoma arises
from a stem cell population that is able to differentiate into
alveolar type II pneumocytes and bronchiolar club cells, from a
lineage-specific progenitor cell, or from a fully differentiated cell
type (93). In mice putative bronchioalveolar stem cells (BASC)
have been identified which are proposed to be the cell type of
origin of lung adenocarcinomas in response to oncogenic K-ras
(94). However, the presence of BASC in humans and sheep has
not been firmly established (95). Cells displaying some features of
BASC have been described in sheep (72, 96) but their significance
in OPA tumourigenesis remains unclear.
As described in the previous section, in the in vivo
experimental lambmodel, JSRV is able to induce the formation of
OPA tumors with a short incubation period (82, 83). In contrast,
adult sheep have been shown to be resistant to experimental
induction of OPA (83). This age-related susceptibility to OPA
tumor formation is due, at least in part, to the availability of
susceptible target cells capable of being infected and transformed.
JSRV, like most retroviruses, infects dividing cells much more
efficiently than non-dividing cells (73). Normal sheep and human
adult lungs have relatively low rates of bronchioalveolar cell
division. However, the lungs of both species are not fully mature
at birth and continue to develop for a period of time resulting in
an increase in alveolar number (97, 98). One study has shown that
the cells targeted for JSRV transformation and tumourigenesis
are proliferating progenitor cells of type II pneumocyte lineage,
termed lung alveolar proliferating cells (LAPCs), rather than
mature post-mitotic type II pneumocytes, bronchiolar club cells,
or BASC. LAPCs are significantly more abundant in lambs
compared to adult sheep, therefore the age-related susceptibility
of OPA development is directly related to the abundance of
LAPCs (73).
The adult lung has significant reparative capabilities despite
the low proliferation rate of respiratory epithelial cells, LAPCs
are proposed to play an important role in tissue repair following
injury. Chemically-induced injury to the respiratory epithelium
has been shown to increase the number of LAPCs in adult
sheep, which subsequently rendered the sheep susceptible to
JSRV infection and transformation (73). This may have relevance
for naturally occurring OPA, as cases typically present with
a variety of other parasitic, bacterial, or viral infections (45).
Classically, these infections were considered as “secondary” to
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JSRV infection; however, it is possible that they are important
factors that contribute to pulmonary inflammation and tissue
damage that facilitate JSRV infection and tumorigenesis. In
humans, recent studies have identified a subpopulation of
type II pneumonocytes that exhibit properties of progenitor
cells, including self-renewal and proliferation in response to
injury (99, 100). Thus, OPA may have value as a comparative
model for understanding the role of alveolar progenitor cells
in carcinogenesis.
OPA DIAGNOSIS AND POTENTIAL
SOURCES OF EXPERIMENTAL ANIMALS
Although OPA has been identified in sheep <1 year old
the majority of naturally occurring clinical cases are seen in
sheep aged between 2 and 4 years of age. The diagnosis of
clinical OPA can usually be based on clinical signs including
pneumonia (non-responsive to antibiotic treatment), dyspnea,
and tachypnoea (especially when herded) in combination with
weight loss (despite maintaining a normal appetite) (101).
Thoracic auscultation may be of benefit for diagnosing advanced
cases, where adventitious lung sounds (crackles) can be heard
over the majority of the lung fields due to the presence of fluid
in the airways (102). Significant volumes of fluid draining from
the nostrils is a pathognomonic clinical sign of OPA (103); at
this stage tumors will typically occupy more than 30% of the lung
volume (101). Although historically these advanced tumors were
presumed to have developed over many months or years (101),
new evidence shows that some OPA tumors may develop very
rapidly (104).
Pre-clinical antemortem diagnosis is important not only for
removing infected animals from flocks but also in identifying
cases for experimental purposes; however, this diagnosis remains
a significant challenge. Pre-clinical diagnosis based on a clinical
examination is difficult as there may be a lack of adventitious
lung sounds detectable by auscultation (105). Many infected
sheep never develop clinical signs during their commercial
lifespan (106), and those that do may only do so when the
tumor is sufficiently large to compromise respiration. During
this pre-clinical period these apparently healthy animals may
be infectious and represent a source of infection for the rest of
the flock.
As JSRV infected sheep fail to produce a significant humoral
immune response to viral proteins (107), it has not been
possible to develop serological diagnostic assays. Alternative
diagnostic tests have been developed for virus detection in
blood samples using PCR technology (108); unfortunately
the numbers of virally infected blood mononuclear cells
(monocytes, B and T lymphocytes) are very low, which results
in high false negative results (109). Despite this significant
limitation, the test can be used for identifying infected flocks
rather than for testing individual animals. The same PCR
technique has been employed to detect JSRV-infected cells
in bronchoalveolar lavage samples (110), which offers better
sensitivity than the blood test. However, this method requires
sedation for sample collection, only tests a small region of
the lung (potential for missing early cases) and does not
lend itself to large-scale routine on-farm testing. Currently,
the gold standard diagnostic test for both clinical and pre-
clinical OPA remains gross pathology and histology performed
at post mortem examination. OPA tumors can be extensive,
involving the entire lung lobe, or may occur as multifocal
discrete lesions. These lesions fail to collapse upon entering
the thoracic cavity and can distort the normal architecture
of the affected lung lobe, with clear boundaries between
tumor tissue and adjacent pink aerated lung. Although the
overlying pleura can remain intact, fibrinous adhesions between
the visceral pleura and chest wall can be seen (Figure 3).
Tracheobronchial and mediastinal lymph nodes usually appear
grossly normal but may be enlarged in cases of metastasis or
pneumonia (39).
Imaging modalities such as radiography and computed
tomography (CT) have been suggested for use in OPA
diagnosis. CT is considered the gold standard imaging modality
for human lung parenchyma and has been used in studies
to monitor the development and progression of OPA in
both naturally occurring (111) and experimentally infected
animals (70). CT will detect smaller lung lesions than can
be identified using radiography, particularly if located in the
ventral margins of the cranial lung lobes that are difficult
to image using radiography (Figure 4). However, radiography
and CT are cost prohibitive for commercial flocks and require
specialized equipment and sedation/general anesthesia (101).
Ultrasonography is an extremely useful imaging technique for
OPA diagnosis and can be performed on-farm in conscious
animals. With experience, the procedure can be performed
in <1min per sheep (112), can differentiate between chronic
lung lesions and can detect OPA lesions as small as 1–2 cm
in diameter involving the visceral pleura (31). One study
conducted transthoracic ultrasound examinations of 100 sheep
presented for the investigation of weight loss with or without
respiratory signs; of these cases, 41 sheep were diagnosed as
OPA positive based on ultrasound examination alone, with
all cases having the diagnosis confirmed at post mortem. The
remaining sheep had no ultrasonographic changes characteristic
of OPA and had no gross OPA lesions at post mortem.
The study demonstrated the high specificity of transthoracic
ultrasound for OPA diagnosis in clinically affected animals,
producing no false positive or negative results (31). Although
a negative scan cannot guarantee that an animal does not
have early OPA and/or is not infected with JSRV, it has been
suggested that transthoracic ultrasound examination can be used
to confirm a suspected diagnosis, screen flock replacements, and
screen sheep in known OPA-affected flocks. It is also an ideal
method for identifying pre-clinical cases for experimental use, as
individual cases can be selected based on the size and location of
OPA lesions.
OPA AS A PRE-CLINICAL MODEL
The use of OPA as a model for monitoring the tumor
microenvironment, assessing the effectiveness of chemo-
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FIGURE 3 | Gross pathology of OPA tumors. (a,b) Large single advanced OPA tumors affecting the entire left cranial lung lobe. The lesions are gray in color with a
clear distinct boundary between neoplastic tissue and the neighboring pink aerated lung. Extensive fibrous tissue can be seen attached to the overlying pleura of the
tumor. (c) Two discrete OPA tumors within the right cranial and caudal lung lobes.
FIGURE 4 | Thoracic CT images of OPA tumors. (a) Axial, (b) Coronal, and (c) Sagittal planes. Three large areas of increased radiopacity are seen within the lung
lobes consistent with advanced OPA tumors (outlined in red). One lesion is present within the dorsal region of the left cranial lung lobe with a further lesion in the
ventral region of the left caudal lung lobe. A smaller lesion is present within the right caudal lung lobe. A patchy and hazy area of increased opacity (ground glass
appearance), with preservation of bronchial and vascular patterns, is present (outlined in yellow) between the two tumors in the left lung lobes. This area is consistent
with regions of neoplastic foci or a secondary pneumonia.
and radiotherapy or in the development of surgical techniques
has not been previously documented. However, if techniques
that are commonly used in the treatment of human lung
cancer patients such as ultrasound, general anesthesia, CT,
and surgery can be incorporated into the OPA model, this
would further demonstrate its potential as an excellent
translational research tool. One paper documented the
use of naturally occurring OPA cases combined with CT
evaluation, post mortem examination/histopathology, trace
element, and liver enzyme activity analysis in a long-term
study evaluating the impact of nutritional selenium on
tumourigenesis and progression (111). This study demonstrated
the potential for the OPA model to be integrated with
multiple techniques to provide comprehensive information
on tumor pathogenesis.
In terms of chemotherapy models, in vitro work using
rat fibroblasts has shown that through AKT degradation,
Hsp90 inhibitors can block the transformation and revert
the phenotype of cells already transformed by JSRV
Env. Hsp90 inhibitors can also reduce the proliferation
of primary and immortalized OPA cell lines (63). The
chemotherapeutic potential of agents such as Hsp90 inhibitors
could be assessed using OPA cases if techniques could be
integrated into the model to assess the tumors response
to treatment.
One current ongoing multidisciplinary project that is using
naturally occurring OPA cases as a pre-clinical translational
model is the Implantable Microsystems for Personalized Anti-
Cancer Therapy (IMPACT) programme at the University of
Edinburgh (113). This project aims to develop novelminiaturized
implantable oxygen and pH sensors that can monitor oxygen
levels and pH within a solid tumor; the identification of
hypoxic and acidic regions within a tumor can lead to more
targeted therapies against these radiation and chemo-resistant
regions. Functionality of these sensors is being validated
following their implantation into OPA tumors using a CT-
guided percutaneous method. This technique is similar to that
used for transthoracic needle biopsies in human patients. If
successful, then studies such as this will provide exciting new
translational opportunities for the OPA model to be used in
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pre-clinical research (see accompanying article, Gray et al.
manuscript submitted)1.
CONCLUSION
As outlined here, OPA has great potential to be used as
an excellent model for studying multiple aspects of human
lung cancer biology. As a result, in vivo and in vitro OPA
experimental models have been developed for the study of
JSRV Env mediated oncogenesis; these have been successfully
used to determine the molecular pathways involved in lung
cancer pathogenesis. However, the potential for OPA to be
used as a pre-clinical animal model for assessing human
lung cancer treatment strategies has yet to be fully exploited.
Naturally occurring OPA cases are readily available from infected
flocks due to the endemic nature of the disease in many
countries and pre-clinical cases can be identified by the use
of ultrasound scanning programmes. The use of naturally
occurring cases could decrease the use of experimentally
induced OPA tumors in lambs, reducing ethical concerns with
1Gray M, Sullivan P, Marland JRK, Greenhalgh SN, Meehan J, Gregson R, et al.
A novel translational ovine pulmonary adenocarcinoma model for human lung
cancer.
this model. Future studies that can integrate techniques
commonly used in the treatment of human lung cancer patients,
such as ultrasound, general anesthesia, CT, and surgery, would
further strengthen the effectiveness of OPA as a pre-clinical
cancer research model.
AUTHOR CONTRIBUTIONS
MG wrote the majority of the manuscript and composed the
majority of the figures with contributions from JMwho wrote the
experimental systems for studying OPA. Critical revisions were
made by MG, JM, PS, JRKM, SG, RG, RC, CW, CC, DG, AM,
and DA. All authors read and approved the final manuscript.
FUNDING
This work was supported by funding from the UK
Engineering and Physical Sciences Research Council,
through the IMPACT programme grant (EP/K-34510/1),
a Wellcome Trust Biomedical Resource Grant to the
Wellcome Trust Critical Care Laboratory for Large
Animals (104972/Z/14/Z) and the Scottish Government
Rural and Environment Science and Analytical Services
Division (RESAS).
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, . Cancer
incidence and mortality worldwide: Sources, methods and major patterns
in GLOBOCAN 2012. Int J Cancer. (2015) 136:359–86. doi: 10.1002/ij
c.29210
2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe
Y, et al. International association for the study of lung cancer/american
thoracic society/european respiratory society international multidisciplinary
classification of lung adenocarcinoma. J Thorac Oncol. (2011) 6:244–
85. doi: 10.1097/JTO.0b013e318206a221
3. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular
pathogenesis of human lung cancer. Biochim Biophys Acta. (1998) 1378:21–
59.
4. Carey FA, Wallace WA, Fergusson RJ, Kerr KM, Lamb D. Alveolar
atypical hyperplasia in association with primary pulmonary
adenocarcinoma: a clinicopathological study of 10 cases. Thorax. (1992)
47:1041–3. doi: 10.1136/thx.47.12.1041
5. Coggins CR. A review of chronic inhalation studies with mainstream
cigarette smoke, in hamsters, dogs, and non-human primates. Toxicol Pathol.
(2001) 29:550–7. doi: 10.1080/019262301317226357
6. Liu J, Johnston MR. Animal models for studying lung cancer and
evaluating novel intervention strategies. Surg Oncol. (2002) 11:217–
27. doi: 10.1016/S0960-7404(02)00053-1
7. Pozzi A. Mouse Models of Lung Cancer, Principles and Practice of Lung
Cancer. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins (2010),
p. 179–187.
8. Lynch CJ. Studies on the relation between tumor susceptibility and heredity:
III. spontaneous tumors of the lung in mice. J Exp Med. (1926) 43:339–
55. doi: 10.1084/jem.43.3.339
9. Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities
and shortcomings. Oncogene. (1999) 18:5318–24. doi: 10.1038/sj.onc.12
03107
10. Stoner GD, Adam-Rodwell G, Morse MA. Lung tumors in strain a
mice: application for studies in cancer chemoprevention. J Cell Biochem.
(1993) 53:95–103.
11. Hoenerhoff MJ, Hong HH, Ton T-V, Lahousse SA, Sills RC. A
review of the molecular mechanisms of chemically induced neoplasia
in rat and mouse models in National Toxicology Program bioassays
and their relevance to human cancer. Toxicol Pathol. (2009) 37:835–
48. doi: 10.1177/0192623309351726
12. SzymanskaH, SitarzM, Krysiak E, Piskorowska J, Czarnomska A, SkurzakH,
et al. Genetics of susceptibility to radiation-induced lymphomas, leukemias
and lung tumors studied in recombinant congenic strains. Int J Cancer.
(1999) 83:674–8. doi: 10.1002/(SICI)1097-0215(19991126)83:5<674::AID-
IJC18>3.0.CO;2-M
13. Mase K, Iijima T, Nakamura N, Takeuchi T, Onizuka M, Mitsui T, et al.
Intrabronchial orthotopic propagation of human lung adenocarcinoma-
characterizations of tumorigenicity, invasion and metastasis. Lung Cancer.
(2002) 36:271–6. doi: 10.1016/S0169-5002(02)00004-1
14. Kozaki K-I, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi
T, et al. Establishment and characterization of a human lung cancer
cell line NCI-H460-LNM35 with consistent lymphogenous metastasis
via both subcutaneous and orthotopic propagation. Cancer Res. (2000)
60:2535–2540.
15. Kuo T-H, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H,
et al. Orthotopic reconstitution of human small-cell lung carcinoma after
intravenous transplantation in SCID mice. Anticancer Res. (1992) 12:1407–
10.
16. Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation
for human tumors as model systems: relevance to metastasis and invasion.
Clin Exp Meta. (1993) 11:5–14. doi: 10.1007/BF00880061
17. Kohno T, Yokota J. How many tumor suppressor genes are
involved in human lung carcinogenesis? Carcinogenesis. (1999)
20:1403–10. doi: 10.1093/carcin/20.8.1403
18. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R. Transgenic
overexpression of IGF-II induces spontaneous lung tumors:
a model for human lung adenocarcinoma. Oncogene. (2003)
22:853–7. doi: 10.1038/sj.onc.1206188
19. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol.
(1998) 16:1207–17. doi: 10.1200/JCO.1998.16.3.1207
20. Hoffman RM. Green fluorescent protein imaging of tumour growth,
metastasis, and angiogenesis in mouse models. Lancet Oncol. (2002) 3:546–
56. doi: 10.1016/S1470-2045(02)00848-3
21. El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined
noninvasive imaging and luminometric quantification of luciferase-labeled
Frontiers in Oncology | www.frontiersin.org 8 April 2019 | Volume 9 | Article 335
Gray et al. Ovine Pulmonary Adenocarcinoma Models
human prostate tumors and metastases. Lab Invest. (2002) 82:1563–
71. doi: 10.1097/01.LAB.0000036877.36379.1F
22. Mainardi S, Mijimolle N, Francoz S, Vicente-Due-as C, Sánchez-
García I, Barbacid M. Identification of cancer initiating cells in K-Ras
driven lung adenocarcinoma. Proc Natl Acad Sci USA. (2014) 111:255–
60. doi: 10.1073/pnas.1320383110
23. Kirschvink N, Reinhold P. Use of alternative animals as asthma models.
Current Drug Targets. (2008) 9:470–84. doi: 10.2174/1389450087845
33525
24. Meeusen EN, Snibson KJ, Hirst SJ, Bischof RJ. Sheep as a model
species for the study and treatment of human asthma and other
respiratory diseases. Drug Discov Today Dis Models. (2009) 6:101–
6. doi: 10.1016/j.ddmod.2009.12.002
25. Plopper CG, Mariassy AT, Wilson DW, Alley JL, Nishio SJ, Nettesheim
P. Comparison of nonciliated tracheal epithelial cells in six mammalian
species: ultrastructure and population densities. Exp Lung Res. (1983) 5:281–
94. doi: 10.3109/01902148309061521
26. Miller HRP. Mucosal mast cells and the allergic response
against nematode parasites. Vet Immunol Immunopathol. (1996)
54:331–6. doi: 10.1016/S0165-2427(96)05696-6
27. Collie D, Pyrah I, Watt NJ. Distribution and quantitation of lung
parenchymal contractile tissue in ovine lentivirus-induced lymphoid
interstitial pneumonia. Do tissue forces limit lung distensibility? Lab Invest.
(1995) 73:441–7.
28. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute
lung injury. Am J Physiol Lung Cell Mol Physiol. (2008) 295:379–
99. doi: 10.1152/ajplung.00010.2008
29. Ackermann MR. Lamb model of respiratory syncytial virus-associated lung
disease: insights to pathogenesis and novel treatments. ILAR J. (2014) 55:4–
15. doi: 10.1093/ilar/ilu003
30. Viard R, Tourneux P, Storme L, Girard J-M, Betrouni N, Rousseau J.
Magnetic resonance imaging spatial and time study of lung water content
in newborn lamb: methods and preliminary results. Invest Radiol. (2008)
43:470–80. doi: 10.1097/RLI.0b013e31816900bb
31. Cousens C, Scott PR. Assessment of transthoracic ultrasound diagnosis
of ovine pulmonary adenocarcinoma in adult sheep. Vet Record. (2015)
177:366–71. doi: 10.1136/vr.103298
32. Radu DM, Seguin A, Bruneval P, Fialaire Legendre A, Carpentier A,
Martinod E. Bronchial replacement with arterial allografts. Ann Thorac Surg.
(2010) 90:252–8. doi: 10.1016/j.athoracsur.2010.03.079
33. Van der Velden J, Barker D, Barcham G, Koumoundouros E, Snibson
K. Assessment of peripheral airway function following chronic allergen
challenge in a sheep model of asthma (small airway function in a sheep
model of asthma). PLoS ONE. (2011) 6:28740. doi: 10.1371/journal.pone.00
28740
34. Abraham WM. Modeling of asthma, COPD and cystic
fibrosis in sheep. Pulmonary Pharmacol Ther. (2008) 21:743–
54. doi: 10.1016/j.pupt.2008.01.010
35. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human
respiratory syncytial virus disease.Am J Physiol Lung Cell Mol Physiol. (2011)
301:148–56. doi: 10.1152/ajplung.00065.2011
36. Youssef G, Wallace WAH, Dagleish MP, Cousens C, Griffiths DJ. Ovine
pulmonary adenocarcinoma: a large animal model for human lung cancer.
Insti Lab Anim Res J. (2015) 56:99–115. doi: 10.1093/ilar/ilv014
37. DeMartini JC, York DF. Retrovirus-associated neoplasms of the respiratory
system of sheep and goats: ovine pulmonary carcinoma and enzootic nasal
tumor. Vet Clin. (1997) 13:55–70.
38. Palmarini M, Fan H, Sharp JM. Sheep pulmonary adenomatosis: a unique
model of retrovirus associated lung cancer. Trends Microbiol. (1997) 5:478–
83. doi: 10.1016/S0966-842X(97)01162-1
39. Griffiths DJ, Martineau HM, Cousens C. Pathology and pathogenesis
of ovine pulmonary adenocarcinoma. J Comp Pathol. (2010) 142:260–
83. doi: 10.1016/j.jcpa.2009.12.013
40. Leroux C, Girard N, Cottin V, Greenland T, Mornex J-F, Archer F. Jaagsiekte
sheep retrovirus (JSRV): from virus to lung cancer in sheep. Vet Res. (2007)
38:211–28. doi: 10.1051/vetres:2006060
41. Tustin R. Ovine jaagsiekte. J South Afr Vet Med Assoc. (1969) 40:3–23.
42. De las Heras M, Gonzalez L, Sharp J. Pathology of ovine
pulmonary adenocarcinoma. In: Fan H, editor. Jaagsiekte Sheep
Retrovirus and Lung Cancer. Berlin; Heidelberg: Springer (2003). p.
25–54. doi: 10.1007/978-3-642-55638-8_2
43. Sanna MP, Sanna E, De Las Heras M, Leoni A, Nieddu A, Pirino S,
et al. Association of jaagsiekte sheep retrovirus with pulmonary carcinoma
in Sardinian mouﬄon (Ovis musimon). J Comp Pathol. (2001) 125:145–
52. doi: 10.1053/jcpa.2001.0489
44. Caporale M, Martineau H, De las Heras M, Murgia C, Huang R, Centorame
P, et al. Host species barriers to Jaagsiekte sheep retrovirus replication and
carcinogenesis. J Virol. (2013) 87:10752–62. doi: 10.1128/JVI.01472-13
45. Fan H. Jaagsiekte Sheep Retrovirus and Lung Cancer. New York, NY: Springer
Science & Business Media (2003). doi: 10.1007/978-3-642-55638-8
46. Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma,
an animal model for lung cancer. J Natl Cancer Institute. (2001) 93:1603–
14. doi: 10.1093/jnci/93.21.1603
47. Dungal N, Gislason G, Taylor E. Epizootic adenomatosis in
the lungs of sheep-comparisons with jaagsiekte, verminous
pneumonia and progressive pneumonia. J Comp Pathol Ther. (1938)
51:46–68. doi: 10.1016/S0368-1742(38)80006-0
48. Sharp J, DeMartini J. Natural history of JSRV in sheep. In: Fan H, editor.
Jaagsiekte Sheep Retrovirus and Lung Cancer. Berlin; Heidelberg: Springer
(2003). p. 55–79. doi: 10.1007/978-3-642-55638-8_3
49. Dungal N. Experiments with Jaagsiekte. Am J Pathol. (1946) 22:737–59.
50. Grego E, De Meneghi D, Álvarez V, Benito AA, Minguijón E, Ortín A,
et al. Colostrum and milk can transmit jaagsiekte retrovirus to lambs. Vet
Microbiol. (2008) 130:247–57. doi: 10.1016/j.vetmic.2008.01.011
51. York DF, Vigne R, Verwoerd DW, Querat G. Nucleotide sequence of the
jaagsiekte retrovirus, an exogenous and endogenous type D and B retrovirus
of sheep and goats. J Virol. (1992) 66:4930–9.
52. Palmarini M, Fan H.Molecular biology of jaagsiekte sheep retrovirus. In: Fan
H, editor. Jaagsiekte Sheep Retrovirus and Lung Cancer. Berlin; Heidelberg:
Springer (2003). p. 81–115. doi: 10.1007/978-3-642-55638-8_4
53. Maeda N, Palmarini M, Murgia C, Fan H. Direct transformation of rodent
fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci USA.
(2001) 98:4449–54. doi: 10.1073/pnas.071547598
54. Cousens C, Maeda N, Murgia C, Dagleish MP, Palmarini M, Fan H. In
vivo tumorigenesis by Jaagsiekte sheep retrovirus (JSRV) requires Y590 in
Env TM, but not full-length orfX open reading frame. Virology. (2007)
367:413–21. doi: 10.1016/j.virol.2007.06.004
55. Caporale M, Cousens C, Centorame P, Pinoni C, De las Heras M, Palmarini
M. Expression of the jaagsiekte sheep retrovirus envelope glycoprotein
is sufficient to induce lung tumors in sheep. J Virol. (2006) 80:8030–
7. doi: 10.1128/JVI.00474-06
56. Wootton SK, Halbert CL, Miller AD. Sheep retrovirus structural protein
induces lung tumours. Nature. (2005) 434:904–7. doi: 10.1038/nature03492
57. Rai SK, Duh F-M, Vigdorovich V, Danilkovitch-Miagkova A,
Lerman MI, Miller AD. Candidate tumor suppressor HYAL2 is a
glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor
for jaagsiekte sheep retrovirus, the envelope protein of which
mediates oncogenic transformation. Proc Natl Acad Sci USA. (2001)
98:4443–8. doi: 10.1073/pnas.071572898
58. Zhou S, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al.
SH2 domains recognize specific phosphopeptide sequences. Cell. (1993)
72:767–78. doi: 10.1016/0092-8674(93)90404-E
59. Cousens C, Alleaume C, Bijsmans E, Martineau HM, Finlayson J, Dagleish
MP, et al. Jaagsiekte sheep retrovirus infection of lung slice cultures.
Retrovirology. (2015) 12:31–47. doi: 10.1186/s12977-015-0157-5
60. De Las Heras M, Ortin A, Benito A, Summers C, Ferrer L, Sharp J. In-
situ demonstration of mitogen-activated protein kinase Erk 1/2 signalling
pathway in contagious respiratory tumours of sheep and goats. J Comp
Pathol. (2006) 135:1–10. doi: 10.1016/j.jcpa.2006.02.002
61. Maeda N, Fu W, Ortin A, de las Heras M, Fan H. Roles of the Ras-
MEK-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-
Akt-mTOR pathways in Jaagsiekte sheep retrovirus-induced transformation
of rodent fibroblast and epithelial cell lines. J Virol. (2005) 79:4440–
50. doi: 10.1128/JVI.79.7.4440–44502005
Frontiers in Oncology | www.frontiersin.org 9 April 2019 | Volume 9 | Article 335
Gray et al. Ovine Pulmonary Adenocarcinoma Models
62. Suau F, Cottin V, Archer F, Croze S, Chastang J, Cordier G, et al. Telomerase
activation in a model of lung adenocarcinoma. Eur Respir J. (2006) 27:1175–
82. doi: 10.1183/09031936.06.00125105
63. Varela M, Golder M, Archer F, de las Heras M, Leroux C, Palmarini
M. A large animal model to evaluate the effects of Hsp90 inhibitors
for the treatment of lung adenocarcinoma. Virology. (2008) 371:206–
15. doi: 10.1016/j.virol.2007.09.041
64. Arnaud F, Caporale M, Varela M, Biek R, Chessa B, Alberti A, et al.
A paradigm for virus-host coevolution: sequential counter-adaptations
between endogenous and exogenous retroviruses. PLoS Pathol. (2007)
3:1716–29. doi: 10.1371/journal.ppat.0030170
65. Cumer T, Pompanon F, Boyer F. Old origin of a protective
endogenous retrovirus (enJSRV) in the Ovis genus. Heredity. (2018)
187–94. doi: 10.1038/s41437-018-0112-z
66. Hecht SJ, Carlson JO, Demartini JC. Analysis of a type D retroviral
capsid gene expressed in ovine pulmonary carcinoma and present in
both affected and unaffected sheep genomes. Virology. (1994) 202:480–
4. doi: 10.1006/viro.1994.1366
67. DeMartini J, Carlson J, Leroux C, Spencer T, Palmarini M. Endogenous
retroviruses related to jaagsiekte sheep retrovirus. In: Fan H, editor.
Jaagsiekte Sheep Retrovirus and Lung Cancer. Berlin; Heidelberg: Springer
(2003). p. 117–37. doi: 10.1007/978-3-642-55638-8_5
68. Palmarini M, Mura M, Spencer TE. Endogenous betaretroviruses of sheep:
teaching new lessons in retroviral interference and adaptation. J Gen Virol.
(2004) 85:1–13. doi: 10.1099/vir.0.19547-0
69. Arnaud F, Murcia PR, Palmarini M. Mechanisms of late
restriction induced by an endogenous retrovirus. J Virol. (2007)
81:11441–51. doi: 10.1128/JVI.01214-07
70. Hudachek SF, Kraft SL, Thamm DH, Bielefeldt-Ohmann H, DeMartini
JC, Miller AD, et al. Lung tumor development and spontaneous
regression in lambs coinfected with jaagsiekte sheep retrovirus and ovine
lentivirus. Vet Pathol Online. (2010) 47:148–62. doi: 10.1177/03009858093
52787
71. Summers C, Norval M, De las Heras M, Gonzalez L, Sharp JM, Woods
GM. An influx of macrophages is the predominant local immune response
in ovine pulmonary adenocarcinoma. Vet Immunol Immunopathol. (2005)
106:285–94. doi: 10.1016/j.vetimm.2005.03.006
72. Martineau HM, Cousens C, Imlach S, Dagleish MP, Griffiths DJ. Jaagsiekte
sheep retrovirus infects multiple cell types in the ovine lung. J Virol. (2011)
85:3341–55. doi: 10.1128/JVI.02481-10
73. Murgia C, Caporale M, Ceesay O, Di Francesco G, Ferri N, Varasano V, et al.
Lung adenocarcinoma originates from retrovirus infection of proliferating
type 2 pneumocytes during pulmonary post-natal development or tissue
repair. PLoS Pathog. (2011) 7:1–12. doi: 10.1371/journal.ppat.1002014
74. Platt J, Kraipowich N, Villafane F, DeMartini J. Alveolar type II cells
expressing jaagsiekte sheep retrovirus capsid protein and surfactant
proteins are the predominant neoplastic cell type in ovine pulmonary
adenocarcinoma. Vet Pathol. (2002) 39:341–52. doi: 10.1354/vp.39-3-341
75. De las Heras M, de Martino A, Borobia M, Ortin A, Alvarez R,
Borderias L, et al. Solitary tumours associated with Jaagsiekte retrovirus
in sheep are heterogeneous and contain cells expressing markers
identifying progenitor cells in lung repair. J Comp Pathol. (2014)
15:138–47. doi: 10.1016/j.jcpa.2013.09.001
76. Cousens C, Bishop JV, Philbey AW, Gill CA, Palmarini M,
Carlson JO, et al. Analysis of integration sites of Jaagsiekte sheep
retrovirus in ovine pulmonary adenocarcinoma. J Virol. (2004)
78:8506–12. doi: 10.1128/JVI.78.16.8506–85122004
77. Demartini JC, Rosadio RH, Lairmore MD. The etiology and pathogenesis
of ovine pulmonary carcinoma (sheep pulmonary adenomatosis). Vet
Microbiol. (1988) 17:219–36. doi: 10.1016/0378-1135(88)90067-3
78. Rosadio R, Lairmore M, Russell H, DeMartini J. Retrovirus-associated
ovine pulmonary carcinoma (sheep pulmonary adenomatosis) and lymphoid
interstitial pneumonia. I. Lesion development and age susceptibility. Vet
Pathol. (1988) 25:475–83. doi: 10.1177/030098588802500611
79. Minguijón E, González L, De las Heras M, Gómez N, García-Goti M,
Juste RA, et al. Pathological and aetiological studies in sheep exhibiting
extrathoracic metastasis of ovine pulmonary adenocarcinoma (jaagsiekte).
J Comp Pathol. (2013) 148:139–47. doi: 10.1016/j.jcpa.2012.06.003
80. Nobel T, Neumann F, Klopfer U. Histological patterns of the metastases
in pulmonary adenomatosis of sheep (jaagsiekte). J Comp Pathol. (1969)
79:537–45. doi: 10.1016/0021-9975(69)90074-7
81. Martin WB, Scott FM, Sharp JM, Angus KW, Norval M. Experimental
production of sheep pulmonary adenomatosis (Jaagsiekte). Nature. (1976)
264:183–7. doi: 10.1038/264183a0
82. Sharp J, Angus K, Gray E, Scott F. Rapid transmission of sheep pulmonary
adenomatosis (jaagsiekte) in young lambs. Arch Virol. (1983) 78:89–
95. doi: 10.1007/BF01310861
83. Salvatori D, Gonzalez L, Dewar P, Cousens C, de las Heras M, Dalziel
RG, et al. Successful induction of ovine pulmonary adenocarcinoma
in lambs of different ages and detection of viraemia during the
preclinical period. J Gen Virol. (2004) 85:3319–24. doi: 10.1099/vir.0.
80333-0
84. York DF, Vigne R, Verwoerd D, Querat G. Isolation, identification,
and partial cDNA cloning of genomic RNA of jaagsiekte retrovirus,
the etiological agent of sheep pulmonary adenomatosis. J Virol. (1991)
65:5061–7.
85. PalmariniM, Sharp JM, De Las HerasM, FanH. Jaagsiekte sheep retrovirus is
necessary and sufficient to induce a contagious lung cancer in sheep. J Virol.
(1999) 73:6964–72.
86. DeMartini JC, Bishop JV, Allen TE, Jassim F, Sharp JM, de las Heras
M, et al. Jaagsiekte sheep retrovirus proviral clone JSRVJS7, derived from
the JS7 lung tumor cell line, induces ovine pulmonary carcinoma and is
integrated into the surfactant protein A gene. J Virol. (2001) 75:4239–
46. doi: 10.1128/JVI.75.9.4239–42462001
87. Linnerth-Petrik NM, Santry LA, Darrick LY, Wootton SK. Adeno-associated
virus vector mediated expression of an oncogenic retroviral envelope protein
induces lung adenocarcinomas in immunocompetent mice. PLoS ONE.
(2012) 7:51400–15. doi: 10.1371/journal.pone.0051400
88. Palmarini M, Sharp JM, Lee C, Fan H. In vitro infection of ovine cell lines by
Jaagsiekte sheep retrovirus. J Virol. (1999) 73:10070–8.
89. Archer F, Jacquier E, Lyon M, Chastang J, Cottin V, Mornex J-F, et al.
Alveolar type II cells isolated from pulmonary adenocarcinoma: a model
for JSRV expression in vitro. Am J Respir Cell Mol Biol. (2007) 36:534–
40. doi: 10.1165/rcmb.2006-0285OC
90. Jassim F, Sharp J, Marinello P. Three-step procedure for isolation of epithelial
cells from the lungs of sheep with jaagsiekte. Res Vet Sci. (1987) 43:407–
9. doi: 10.1016/S0034-5288(18)30815-4
91. Johnson C, Fan H. Three-dimensional culture of an ovine pulmonary
adenocarcinoma-derived cell line results in re-expression of
surfactant proteins and Jaagsiekte sheep retrovirus. Virology. (2011)
414:91–6. doi: 10.1016/j.virol.2011.03.018
92. Sanderson MJ. Exploring lung physiology in health and
disease with lung slices. Pulmonary Pharmacol Ther. (2011)
24:452–65. doi: 10.1016/j.pupt.2011.05.001
93. Reynolds SD, Hong KU, Giangreco A, Mango GW, Guron C, Morimoto
Y, et al. Conditional Clara cell ablation reveals a self-renewing progenitor
function of pulmonary neuroendocrine cells. Am J Physiol Lung Cell Mol
Physiol. (2000) 278:1256–63. doi: 10.1152/ajplung.2000.278.6.L1256
94. Kim CFB, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al.
Identification of bronchioalveolar stem cells in normal lung and lung cancer.
Cell. (2005) 121:823–35. doi: 10.1016/j.cell.2005.03.032
95. Lundin A, Driscoll B. Lung cancer stem cells: progress and prospects. Cancer
Lett. (2013) 338:89–93. doi: 10.1016/j.canlet.2012.08.014
96. Archer F, Abi-Rizk A, Desloire S, Dolmazon C, Gineys B, Guiguen F,
et al. Lung progenitors from lambs can differentiate into specialized
alveolar or bronchiolar epithelial cells. BMC Vet Res. (2013) 9:224–
37. doi: 10.1186/1746-6148-9-224
97. Zeltner TB, Caduff JH, Gehr P, Pfenninger J, Burri PH. The postnatal
development and growth of the human lung. Morphometry I. Respir Physiol.
(1987) 67:247–67. doi: 10.1016/0034-5687(87)90057-0
98. Zeltner TB, Burri PH. The postnatal development and growth
of the human lung. IMorphology I. Respir Physiol. (1987)
67:269–82. doi: 10.1016/0034-5687(87)90058-2
99. Nabhan AN, Brownfield DG, Harbury PB, Krasnow MA, Desai TJ. Single-
cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science.
(2018) 359:1118–23. doi: 10.1126/science.aam6603
Frontiers in Oncology | www.frontiersin.org 10 April 2019 | Volume 9 | Article 335
Gray et al. Ovine Pulmonary Adenocarcinoma Models
100. Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, et al.
Regeneration of the lung alveolus by an evolutionarily conserved epithelial
progenitor. Nature. (2018) 555:251–5. doi: 10.1038/nature25786
101. Scott P, Griffiths D, Cousens C. Diagnosis and control of ovine
pulmonary adenocarcinoma (Jaagsiekte). In Practice. (2013) 35:382–
97. doi: 10.1136/inp.f4427
102. Scott P, Collie D, McGorum B, Sargison N. Relationship between thoracic
auscultation and lung pathology detected by ultrasonography in sheep. Vet J.
(2010) 186:53–7. doi: 10.1016/j.tvjl.2009.07.020
103. Cousens C, Thonur L, Imlach S, Crawford J, Sales J, Griffiths DJ. Jaagsiekte
sheep retrovirus is present at high concentration in lung fluid produced
by ovine pulmonary adenocarcinoma-affected sheep and can survive for
several weeks at ambient temperatures. Res Vet Sci. (2009) 87:154–
6. doi: 10.1016/j.rvsc.2008.11.007
104. Scott PR, Dagleish MP, Cousens C. Development of superficial lung
lesions monitored on farm by serial ultrasonographic examination in
sheep with lesions confirmed as ovine pulmonary adenocarcinoma
at necropsy. Irish Vet J. (2018) 71:23–9. doi: 10.1186/s13620-018-
0134-0
105. Cousens C, Graham M, Sales J, Dagleish MP. Evaluation of the efficacy of
clinical diagnosis of ovine pulmonary adenocarcinoma. Vet Record. (2008)
162:88–95. doi: 10.1136/vr.162.3.88
106. Caporale M, Centorame P, Giovannini A, Sacchini F, Di Ventura M, de las
Heras M, et al. Infection of lung epithelial cells and induction of pulmonary
adenocarcinoma is not the most common outcome of naturally occurring
JSRV infection during the commercial lifespan of sheep. Virology. (2005)
338:144–53. doi: 10.1016/j.virol.2005.05.018
107. Ortín ME, Dewar P, García M, Ferrer LM, Palmarini M, Gonzalez
L, et al. Lack of a specific immune response against a recombinant
capsid protein of Jaagsiekte sheep retrovirus in sheep and goats naturally
affected by enzootic nasal tumour or sheep pulmonary adenomatosis. Vet
Immunol Immunopathol. (1998) 61:229–37. doi: 10.1016/S0165-2427(97)
00149-9
108. De las Heras M, Ortín A, Salvatori D, de Villareal MP, Cousens C, Ferrer LM,
et al. A PCR technique for the detection of Jaagsiekte sheep retrovirus in the
blood suitable for the screening of ovine pulmonary adenocarcinoma in field
conditions. Res Vet Sci. (2005) 79:259–64. doi: 10.1016/j.rvsc.2005.02.003
109. Lewis FI, Brülisauer F, Cousens C, McKendrick IJ, Gunn GJ. Diagnostic
accuracy of PCR for Jaagsiekte sheep retrovirus using field data from 125
Scottish sheep flocks. Vet J. (2011) 187:104–8. doi: 10.1016/j.tvjl.2009.10.024
110. Voigt K, Brügmann M, Huber K, Dewar P, Cousens C, Hall M, et al. PCR
examination of bronchoalveolar lavage samples is a useful tool in pre-clinical
diagnosis of ovine pulmonary adenocarcinoma (Jaagsiekte). Res Vet Sci.
(2007) 83:419–27. doi: 10.1016/j.rvsc.2007.02.001
111. Humann-Ziehank E, Renko K, Bruegmann ML, Devi VR, Hewicker-
Trautwein M, Andreae A, et al. Long-term study of ovine pulmonary
adenocarcinogenesis in sheep with marginal vs. sufficient nutritional
selenium supply: results from computed tomography, pathology,
immunohistochemistry, JSRV-PCR and lung biochemistry. J Trace Elem
Med Biol. (2013) 27:391–9. doi: 10.1016/j.jtemb.2013.03.002
112. Scott P, Cousens C. Ultrasonography of ovine pulmonary adenocarcinoma.
In Practice. (2018) 40:291–300. doi: 10.1136/inp.k3380
113. Marland JRK, Blair EO, Flynn BW, González-Fernández E, Huang L,
Kunkler IH, et al. Implantable microsystems for personalised anticancer
therapy. In: Mitra S, Cumming DRS, editors. CMOS Circuits for Biological
Sensing and Processing. Cham: Springer International Publishing (2018).
p. 259–86. doi: 10.1007/978-3-319-67723-1_11
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Gray, Meehan, Sullivan, Marland, Greenhalgh, Gregson, Clutton,
Ward, Cousens, Griffiths, Murray and Argyle. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 11 April 2019 | Volume 9 | Article 335
